Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 4 5Phase EARLY_PHASE1 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 82Glioma 66Brain Neoplasms 60Neuroblastoma 14Astrocytoma 14Neoplasms 10Medulloblastoma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Meningioma 7Diffuse Intrinsic Pontine Glioma 7Central Nervous System Neoplasms 7Sarcoma 6Recurrence 6Neoplasm Metastasis 6Melanoma 6Lung Neoplasms 6Ependymoma 6Osteosarcoma 4Neuroma, Acoustic 4Lymphoma, Follicular 4Squamous Cell Carcinoma of Head and Neck 3Rhabdoid Tumor 3Prostatic Neoplasms 3Pheochromocytoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neurofibromatosis 2 3Lymphoma 3

Interventions

brivaracetam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Epilepsy × CNS × Clear all
NCT05029960 2026-06-03

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

University of Rochester

Phase EARLY_PHASE1 Terminated
3 enrolled
CNS

Brain Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡